LLY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LLY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-21), Eli Lilly and Co's current share price is $805.85. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $29.78. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 27.06.
The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 27.10. The lowest was 2.48. And the median was 4.94.
LLY's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Eli Lilly and Co's adjusted revenue per share data for the three months ended in Mar. 2024 was $9.701. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $29.78 for the trailing ten years ended in Mar. 2024.
The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 12.48 | 16.73 | 18.76 | 20.20 | 26.12 |
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 805.85 | / | 29.78 | |
= | 27.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 9.701 | / | 131.7762 | * | 131.7762 | |
= | 9.701 |
Current CPI (Mar. 2024) = 131.7762.
Eli Lilly and Co Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 4.585 | 100.560 | 6.008 |
201409 | 4.538 | 100.428 | 5.955 |
201412 | 4.786 | 99.070 | 6.366 |
201503 | 4.353 | 99.621 | 5.758 |
201506 | 4.672 | 100.684 | 6.115 |
201509 | 4.656 | 100.392 | 6.112 |
201512 | 5.048 | 99.792 | 6.666 |
201603 | 4.576 | 100.470 | 6.002 |
201606 | 5.098 | 101.688 | 6.606 |
201609 | 4.894 | 101.861 | 6.331 |
201612 | 5.414 | 101.863 | 7.004 |
201703 | 4.950 | 102.862 | 6.341 |
201706 | 5.510 | 103.349 | 7.026 |
201709 | 5.358 | 104.136 | 6.780 |
201712 | 3.127 | 104.011 | 3.962 |
201803 | 4.728 | 105.290 | 5.917 |
201806 | 5.421 | 106.317 | 6.719 |
201809 | 5.171 | 106.507 | 6.398 |
201812 | 5.520 | 105.998 | 6.862 |
201903 | 5.175 | 107.251 | 6.358 |
201906 | 6.096 | 108.070 | 7.433 |
201909 | 5.963 | 108.329 | 7.254 |
201912 | 6.678 | 108.420 | 8.117 |
202003 | 6.427 | 108.902 | 7.777 |
202006 | 6.037 | 108.767 | 7.314 |
202009 | 6.299 | 109.815 | 7.559 |
202012 | 8.137 | 109.897 | 9.757 |
202103 | 7.459 | 111.754 | 8.795 |
202106 | 7.403 | 114.631 | 8.510 |
202109 | 7.436 | 115.734 | 8.467 |
202112 | 8.642 | 117.630 | 9.681 |
202203 | 8.617 | 121.301 | 9.361 |
202206 | 7.186 | 125.017 | 7.575 |
202209 | 7.680 | 125.227 | 8.082 |
202212 | 8.069 | 125.222 | 8.491 |
202303 | 7.705 | 127.348 | 7.973 |
202306 | 9.208 | 128.729 | 9.426 |
202309 | 10.556 | 129.860 | 10.712 |
202312 | 10.349 | 129.419 | 10.537 |
202403 | 9.701 | 131.776 | 9.701 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lilly Endowment Inc | 10 percent owner | 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208 |
Donald A Zakrowski | officer: Chief Accounting Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Alonzo Weems | officer: SVP, ERM & CECO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Patrik Jonsson | officer: SVP and Pres., Lilly Bio-Meds | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Anne E. White | officer: SVP & Pres-Lilly Oncology | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Eric Dozier | officer: EVP, HR & Diversity | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Jackson P Tai | director | |
Mary Lynne Hedley | director | C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451 |
Marschall S Runge | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Naarden Jacob Van | officer: SVP, CEO LoxoONC, Pres LlyONC | C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Diogo Rau | officer: SVP & CIDO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Edgardo Hernandez | officer: SVP & Pres., Mfg. Operations | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Kimberly H Johnson | director | C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005 |
Anat Ashkenazi | officer: SVP & CFO | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Gabrielle Sulzberger | director | 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024